Tiselius Catarina, Johansen Fanny, Rosenblad Andreas, Smedh Kenneth
Institution for Surgical Sciences, Uppsala University, Uppsala, Sweden.
Centre for Clinical research, Västmanlands sjukhus Västerås, Västerås, Sweden.
BMC Cancer. 2025 Jun 10;25(1):1016. doi: 10.1186/s12885-025-14254-1.
Health-related quality of life (HRQoL) is associated with survival in patients with cancer; however, there are few studies on the risk of cancer recurrence. We investigated whether HRQoL can predict disease-free and overall survival (DFS/OS) in patients with non-metastatic colon cancer.
This population-based prospective study investigated patients diagnosed with colon cancer between 2012 and 2016. The 30-item European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) was used to measure HRQoL at diagnosis. Cox proportional hazard regression analyses were used to analyse the association between QLQ-C30 scores and DFS/OS.
Of the 323 patients with non-metastatic colorectal cancer, n = 41 (12.7%) were diagnosed with recurrence during mean (standard deviation) DFS and OS follow-up times of 5.9 (2.9) and 6.2 (2.7) years, respectively. Cox regression analysis of HRQoL, adjusted for important clinical and demographic variables, showed that a higher global health status was significantly associated with an improved DFS (hazard ratio [HR] 0.86 per 10 points; 95% confidence interval [CI] 0.79-0.94; P < 0.001) as well as OS (HR 0.88 per 10 points; 99% CI 0.80-0.96; P = 0.003).
These results demonstrate that HRQoL can predict both DFS and OS in patients with non-metastatic colon cancer. HRQoL should be considered an additional tool in non-metastatic cancer for assessing patients at risk of metastatic disease.
ClinicalTrials.gov (NCT03910894).
健康相关生活质量(HRQoL)与癌症患者的生存相关;然而,关于癌症复发风险的研究较少。我们调查了HRQoL是否能预测非转移性结肠癌患者的无病生存期和总生存期(DFS/OS)。
这项基于人群的前瞻性研究调查了2012年至2016年间被诊断为结肠癌的患者。采用30项欧洲癌症研究与治疗组织核心生活质量问卷(EORTC QLQ-C30)在诊断时测量HRQoL。采用Cox比例风险回归分析来分析QLQ-C30评分与DFS/OS之间的关联。
在323例非转移性结直肠癌患者中,分别在平均(标准差)DFS和OS随访时间5.9(2.9)年和6.2(2.7)年期间,有n = 41例(12.7%)被诊断为复发。对HRQoL进行Cox回归分析,并对重要的临床和人口统计学变量进行校正,结果显示,较高的总体健康状况与改善的DFS(每10分风险比[HR] 0.86;95%置信区间[CI] 0.79 - 0.94;P < 0.001)以及OS(每10分HR 0.88;99% CI 0.80 - 0.96;P = 0.003)显著相关。
这些结果表明,HRQoL可以预测非转移性结肠癌患者的DFS和OS。HRQoL应被视为非转移性癌症中评估有转移疾病风险患者的一种额外工具。
ClinicalTrials.gov(NCT03910894)。